Search company, investor...
Gamida Cell company logo

Gamida Cell

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Gamida Cell

Gamida Cell is a provider in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of cell therapeutics to effectively treat debilitating and often fatal illnesses such as cancer, cardiac disease and peripheral vascular disease.

Headquarters Location

673 Boylston Street 4th Floor

Boston, Massachusetts, 02116,

United States

+1 (978) 494-4632

Missing: Gamida Cell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gamida Cell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Gamida Cell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gamida Cell is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Gamida Cell Patents

Gamida Cell has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Stem cells, Clusters of differentiation, Developmental biology, Cell biology


Application Date


Grant Date



Related Topics

Transcription factors, Stem cells, Clusters of differentiation, Developmental biology, Cell biology



Latest Gamida Cell News

FDA Delays Decision Date on Gamida Cell BLA

Nov 28, 2022

November 28, 2022 The FDA has pushed back its decision date for Gamida Cell’s Biologics License Application (BLA) for omidubicel — a drug that treats patients with blood cancer in need of a bone marrow transplant —by three months. The delay follows the agency’s request for laboratory results for intermediate time points in a phase 3 study. The FDA viewed the company’s response as a major amendment resulting in an extension of the decision date from Jan. 30 to May 1, 2023. Omidubicel showed a statistically significant reduction in time to begin blood cell healing when compared to standard umbilical cord blood in an international phase 3 study of patients with hematologic malignancies undergoing allogeneic bone marrow transplant. The study also showed reduced infections and fewer days of hospitalization in participants who received the drug.

Gamida Cell Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Gamida Cell Rank

Gamida Cell Frequently Asked Questions (FAQ)

  • When was Gamida Cell founded?

    Gamida Cell was founded in 1998.

  • Where is Gamida Cell's headquarters?

    Gamida Cell's headquarters is located at 673 Boylston Street, Boston.

  • What is Gamida Cell's latest funding round?

    Gamida Cell's latest funding round is IPO.

  • How much did Gamida Cell raise?

    Gamida Cell raised a total of $111.6M.

  • Who are the investors of Gamida Cell?

    Investors of Gamida Cell include Israel Immigration Absorption Ministry, Israel Healthcare Ventures, Novartis, Clal Biotechnology Industries, Shavit Capital Fund and 18 more.

  • Who are Gamida Cell's competitors?

    Competitors of Gamida Cell include Scancell, Stemina Biomarker Discovery, Auspex Pharmaceuticals, iPierian, Fate Therapeutics, Pervasis Therapeutics, Amorcyte, Gemin X, Marcadia Biotech, Nuon Therapeutics and 15 more.

Compare Gamida Cell to Competitors

Reality Unlimited

Exploring possible uses of modern molecular biology and cell technologies in the treatment of disease.


NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

Kardia Therapeutics

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

APT Therapeutics

APT Therapeutics develops acute-use drugs for controlling clot formation in stroke, pulmonary embolism, myocardial infarction, deep vein thrombosis, and transplantation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.